🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
7.04
-0.20 (-2.76%)
At close: Nov 20, 2026, 4:00 PM EST
7.03
-0.01 (-0.14%)
After-hours: Nov 20, 2026, 7:30 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

The pipeline spans EVO301 in atopic dermatitis and ulcerative colitis, an MRGPRX2 migraine inhibitor, and oral VAV1 and TLR7/8 programs, with multiple 2027–28 catalysts. $290M cash is expected to fund operations through H2 2029.

Operator

Good afternoon, everyone. Welcome to the 2026 Jefferies Global Healthcare Conference. Today, we're very pleased to have Evommune and Luis Peña, CEO. Thank you very much.

Luis Peña
Co-Founder, President, and CEO, Evommune

Thanks. Thank you, and thank you to Jefferies for having us, and for all of you that are here. We're excited to talk about Evommune today. Evommune's a company that's been around for six years now, and our focus since the inception has been on developing novel assets for chronic inflammation and to build a robust pipeline around that. You have the normal forward-looking statements and disclaimers. In those six years now, we have built what is now a very robust pipeline, with a number of novel targets and multiple data readouts over the next couple of years. Our lead, EVO301, which is an IL-18 binding protein, is about to initiate studies in 2027, both in atopic dermatitis and ulcerative colitis. The atopic dermatitis trial is going to be a robust phase II-B study with three different arms versus placebo.

That'll start mid-next year and read out in 2028. This follows after some pretty exciting phase II-A data, which I'll talk about later. We're also going to initiate a phase II-A trial in ulcerative colitis in the first half of 2027 that'll also read out in 2028. Second program that's in phase II is an MRGPRX2 oral inhibitor. This is currently enrolling in a robust 330-patient migraine trial, and that study is going to read out in the second half of 2027. We're also excited to start introducing and going into the clinic with two different orals. One is an oral VAV1 molecular glue degrader that we just in-licensed. We announced this last week. We have a great collaboration with Hinova, a company from China, with an exquisite molecule, and we're imminently starting a phase I trial.

They actually are going to run the phase I trial, and then we will be in charge of global development. VAV1 is a very exciting target that we'll talk about in more detail as an oral, very potent molecule, and that will start the phase I trial, and we're going to have that data available with biomarker data, including possibly some RA patient arms in the first half of 2027. Last but not least, we have an oral TLR7/8 inhibitor. You probably have heard about some of the exciting Beeline data in SLE recently. We have our own molecule that's very potent that will enter the clinic in the first half of next year, and then it'll read out in 2027. Multiple clinical data sets over 2027 and 2028. We're well-funded.

We have raised capital at the right times with positive data sets, and we have $290 million in cash that take us through the second half of 2029. Enough funding for all of these readouts, so that we don't have to raise capital, and we can raise capital and be opportunistic around positive data going forward. Robust pipeline that we're very excited about. Let's start to talk about each program independently. Our lead, as I mentioned, headed in two phase II studies, is an IL-18 binding protein. We love this molecule. IL-18 is a molecule that's ubiquitously involved in chronic inflammation across a number of indications, so much so that there's a naturally occurring binding protein of the molecule. The problem with the wild-type binding protein is that it gets cleared very rapidly, so that you would have to dose it three times a day.

But there is a very exciting molecule that we have, which is the IL-18 binding protein that's bound to a fragment of antibody that allows it to bind to albumin, and that increases the half-life to such that we can dose it likely once a month once we get into the maintenance phases in phase III. We've already shown very exciting data here. As you see on the left here, we did a phase II-A study in atopic dermatitis, and what you're seeing there is a percent change of EASI versus placebo. This was with really suboptimal dosing. We dosed at day zero and day 28 with a 5 mg per kg dose, and the reason we didn't dose further is because we didn't have tox coverage, but we wanted some initial readout on the IL-18.

And with only dosing out to a month, at week 12, we saw some pretty impressive data, which was that we had a mid-30% separation in active over placebo. That compares very well historically, even though it's tough to do comparison to apples to apples across studies, but it compares very well to any of the current biologics that are out there, including DUPIXENT and EBGLYSS, which we actually developed into phase III in our previous life at Dermira. Very exciting data, and we are really looking forward to dose optimizing. When we talk about our phase II-B study, that we're going to start mid-next year, and we're scaling up our manufacturing for that, we already have a subQ formulation ready to roll. We're going to be looking at three different arms of active versus placebo.

We're going to look at two Q4W arms that are dosed out to 16 weeks, and then we're also going to look at a Q2W arm. In that induction phase out to 16 weeks, it's very important to be aggressive. With dosing, historically, biologics that have loading doses and aggressive dosing initially through week 16 do very well. And then we have a long enough half-life that as we go into the maintenance phase of phase III, we should be able to do quite well. We're really looking forward to initiating that trial. Along with the strong efficacy results that we saw in the phase II-A study, it's been exquisitely well tolerated. There's no conjunctivitis with the drug, and we think that that'll do well and serve well as really first-line therapy, as a monotherapy in atopic dermatitis going forward.

That starts in mid 2027. We are also going to start an ulcerative colitis trial with this drug, with our IV drug actually, so we can start to do life cycle management early. Both of those will read out in 2028. So, great opportunity, and we are certainly excited about this biologic. Second in line, we have a molecule in phase II-B now. This is an oral MRGPRX2 inhibitor. It is an interesting target in that it is expressed both in mast cells as well as in neurons. For the skin, it is more sensory neurons. It is in the trigeminal neurons in the meningeal space. We initiated this migraine study some time ago. It is enrolling quite well, and we are testing two doses of this oral MRGPRX2 inhibitor, a 25 mg BID dose and a 50 mg BID dose versus placebo.

Pretty robust trial, 330 patients, that is going to read out second half of next year. The primary endpoint will be the mean change from baseline and monthly migraine days, and we are enriching for a more severe migraine population, which you normally do in these phase II trials. Even at 330 patients, it is actually somewhat of a limited sample size for migraine. But we are excited, and there is a number of data sets, both pre-clinically and clinically, to suggest that this could work quite well in migraine.

Pre-clinically, you can actually induce multiple ligands that drive mast cell activation, as well as neuropeptide activation in neurons. This is PACAP, VIP, and substance P. All of these have shown migraine induction in mouse models, excuse me. Then also, they have been infused in humans. So these three different ligands have been infused in migraine patients, and they all induce migraine.

What was exciting in the last couple of years, Lundbeck, which you might be familiar with, has a PACAP monoclonal that they dose patients with, and they were able to show a reduction in migraine days over placebo. So, pretty exciting data. We believe it is validation that by blocking these ligands, or at least by blocking the X2 receptor from these ligands, you have an opportunity to have efficacy in migraine patients. With PACAP, X2 is not the only receptor. For example, PAC1 is another receptor. Amgen had an antibody versus PAC1 that did not show efficacy. So, the evidence suggests that X2 may be an important receptor there. So, we think that this could be an important addition for migraine patients, and this robust trial will read out second half of next year.

Third molecule or program in the pipeline that we are going into the clinic with imminently, we had just announced very recently. This is a collaboration with Hinova. Hinova is a company that is in China and have developed a number of very exciting molecules. This is a VAV1 molecular glue degrader. It is really the only way to really go after this target. It is to this point been undruggable unless you degrade it. It is a very exciting target in that it impacts both T and B cell signaling, antigen signaling, but does not hit the majority of the cytokines that JAK inhibitors do. The goal there would be to have some pretty aggressive immunosuppression, but without the cardiovascular effects that you see with the JAKs.

That is pretty exciting to think about because that really opens up the world of multiple indications that you see with the over 10 JAK inhibitors now that are out there clinically and commercially. So, very established market, and we think that this VAV1 target has great opportunity. Of course, we are going to have to prove that clinically, but our expectation is that we will see efficacy across multiple indications, that we are not going to see We are going to be able to separate the cardiovascular effects that you see with the JAK inhibitors, and that will really open up all of those indications to the VAV1 field. Novartis is already out there. You probably saw a deal with Monte Rosa that was pretty significant for a preclinical asset. They paid, I think, $150 million upfront for it, validating that excitement in the target.

We actually had a much more modest upfront for it. We were pretty aggressive in terms of convincing Hinova that we should be a great partner for them, that we move quickly. They actually not only allowed us to have a more modest upfront, but they are actually sharing some of the development costs. We are in charge of global development for this program and asset, but we think Hinova is a great partner, and as I said, they will be paying for part of the development. This molecule is significantly more potent than the Monte Rosa molecule. The chemistry is one novel in that there is a good freedom to operate given that it is a very novel IP.

A lot of the preclinical assets that are out there, and by the way, we have been looking now for about two years into this target and have had 14 molecules in our hands that we have compared directly, and this was by far the one we liked the most. One, from the perspective that it is the most potent, it is the cleanest, it meets all the Lipinski's rules , it is very soluble, but also the IP is most distinct.

It is exactly where we want to land. So when we saw it, we had it in our hands, we immediately knew that we wanted to go after it aggressively. So, it is a great collaboration. We are very excited about it. The U.S. IND is already open. It is imminent in terms of starting the phase I study. We will do the typical single ascending dose, multiple ascending dose study.

There will be an opportunity for us to measure biomarkers at the end of that, and that is going to read out middle of next year. We may add a couple of arms, of patient arms to that study on the multiple ascending dose to higher doses. Our initial indication, even though many indications are available, and Novartis initially is in Sjögren's and PsA, will be RA. There is a good opportunity for an oral in RA, especially with a novel target like this. We have a good ability to do trials both in the U.S. and externally, and this is a target that should do quite well there. That said, it should be a target that is exquisite for life cycle management and many other indications. We will initiate that RA study in the second half of 2027, so that will be exciting to roll quickly into that study.

Given how Sjögren's is a bit tough to enroll, we wouldn't be surprised if we were able to catch up with this program. Yeah, exciting entrant into our pipeline. Last but not least, we have a TLR7/8 antagonist for autoimmune disease. Highly potent molecule. This is a QD oral drug. There's been some very, very recent data which showed significant efficacy in SLE, as you all know, a very, very tough indication. They were able, Beeline showed this data, it was very well received, where you had a really incredible efficacy in SRI-4 scores versus placebo in the mid-60s versus placebo in the mid-30s. It's really been both genetically but clinically validated.

The TLR7 itself is interesting that it blocks type I interferon as well as autoantibody-producing B cells, allowing it to have a broad enough profile to work in an indication like lupus. We will be entering the clinic the first half of next year. Very potent molecule. It's clean from a safety pharmacology perspective. We don't see it lighting up any of the safety pharmacology studies that you normally do early on. Again, very well-behaved molecule in terms of meeting all the Lipinski's rules, highly soluble, and very distinct IP from anything that's out there. Excited about this. We will put it into the phase I study. Again, biomarkers are going to be important given that you already have robust clinical efficacy here. If we show a reduction in biomarkers with this molecule, then we will be in play.

Of course, we'll be measuring the safety as well. That data should be available in the second half of 2027. Robust pipeline, and we even have molecules behind this. We have STAT6 inhibitors and degraders, but just focusing on what we have clinically. Again, to focus on catalyst-rich outcomes and to summarize, in the first half of 2027, we'll initiate the phase II-A ulcerative colitis trial in EVO301. We'll initiate phase I studies with our VAV1 and TLR7/8 inhibitors. In mid-2027, we'll initiate our phase II-B study in atopic dermatitis, and then have our healthy volunteer biomarker data available for our VAV1 asset. In the second half of 2027, we'll have our phase II-B dataset in migraine with our oral MRGPRX2 inhibitor. We'll initiate the RA study with our VAV1 program, and then we'll have the phase I healthy volunteer data with our TLR7/8.

In 2028, we'll have the ulcerative colitis and AD data with our IL-18 binding protein, and then we'll initiate phase II with our TLR7/8. Incredibly robust data sets, a lot of work to do. I'm a chef, I love to cook, and when I'm putting broad menus together, I'm thinking, "Man, this is going to be a lot of work." We've got a lot of work here, but we've got a great team to do it collectively. The team that is leading this has 28 approved NDAs under our belt that we led, so a lot of experience here, a lot of experience in the company, and we're looking forward to driving this robust pipeline forward. Thank you all for your time, and given that we have a little time left here, I'm happy to take any questions if there are any. Thank you.